US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invesco SteelPath MLP & Energy Infrastructure ETF

23.86

-0.0982-0.41%

Post-market: 23.980.1243+0.52%16:04 EDT

Volume:1.02K

Turnover:24.39K

Market Cap:36.50M

PE:- -

High:23.98

Open:23.98

Low:23.86

Close:23.96

52wk High:25.72

52wk Low:21.07

Shares:1.53M

Float Shares:1.53M

Volume Ratio:0.05

T/O Rate:0.07%

Dividend:0.45

Dividend Rate:1.89%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

TruGolf Reports 2024 Financial Results

Stratasys Secures $120 Million Investment from Fortissimo Capital

Press Release: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Ernexa Therapeutics Closes New Funding Round

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Oncology Institute, Inc. Prepares for PIPE Financing

Ostin Technology Completes PIPE Agreement, Expands Share Capital

Press Release: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Press Release: Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

USA Rare Earth and Inflection Point Acquisition Corp. II Announce Closing of Business Combination and Upsized PIPE Funding

Press Release: Aadi Bioscience Announces Closing of $100 Million PIPE Financing

Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Healthcare Triangle, Inc Announces $15.2 Million PIPE Offering

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Invesco Ltd. (IVZ): Among Top Stocks to Buy of Joe DiMenna’s Portfolio

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PIPE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PIPE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PIPE\",,,,,undefined,":{"symbol":"PIPE","market":"US","secType":"STK","nameCN":"Invesco SteelPath MLP & Energy Infrastructure ETF","latestPrice":23.8573,"timestamp":1754683200000,"preClose":23.9555,"halted":0,"volume":1017,"hourTrading":{"tag":"盘后","latestPrice":23.9816,"preClose":23.8573,"latestTime":"16:04 EDT","volume":2,"amount":47.7146,"timestamp":1754683448994},"delay":0,"floatShares":1530001,"shares":1530001,"eps":0,"marketStatus":"Market Closed","change":-0.0982,"latestTime":"08-08 16:00:00 EDT","open":23.9816,"high":23.9816,"low":23.8573,"amount":24389.6471,"amplitude":0.005189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754899200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":23.9555,"sharesOutstanding":1530001,"nav":23.95869,"aum":36508135.74,"dividendRate":0.018862,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.9816,"preClose":23.8573,"latestTime":"16:04 EDT","volume":2,"amount":47.7146,"timestamp":1754683448994},"volumeRatio":0.049698000570418704},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PIPE\",,,,,undefined,":{"symbol":"PIPE","floatShares":1530001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.049698000570418704,"shares":1530001,"dividePrice":0.45,"high":23.9816,"amplitude":0.005189,"preClose":23.9555,"low":23.8573,"week52Low":21.0715,"pbRate":"--","week52High":25.72,"institutionHeld":0,"latestPrice":23.8573,"eps":0,"divideRate":0.018862,"volume":1017,"delay":0,"ttmEps":0,"open":23.9816,"prevYearClose":24.69,"prevWeekClose":24.0726,"prevMonthClose":24.2013,"prevQuarterClose":24.4976,"fiveDayClose":24.0726,"twentyDayClose":23.8806,"sixtyDayClose":24.1312},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PIPE\",params:#limit:5,,,undefined,":[{"date":"2025-07-21","symbol":"PIPE","amount":0.09,"announcedDate":"2025-07-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-21","defaultRemindTime":1753104600000,"name":"Invesco SteelPath MLP & Energy Infrastructure ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-25","payableDate":"2025-07-21","currency":"USD","dateTimestamp":1753070400000,"payDate":"2025-07-25"},{"date":"2025-06-23","symbol":"PIPE","amount":0.09,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco SteelPath MLP & Energy Infrastructure ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-05-19","symbol":"PIPE","amount":0.09,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-19","defaultRemindTime":1747661400000,"name":"Invesco SteelPath MLP & Energy Infrastructure ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-23","payableDate":"2025-05-19","currency":"USD","dateTimestamp":1747627200000,"payDate":"2025-05-23"},{"date":"2025-04-21","symbol":"PIPE","amount":0.09,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-21","defaultRemindTime":1745242200000,"name":"Invesco SteelPath MLP & Energy Infrastructure ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-25","payableDate":"2025-04-21","currency":"USD","dateTimestamp":1745208000000,"payDate":"2025-04-25"},{"date":"2025-03-24","symbol":"PIPE","amount":0.09,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco SteelPath MLP & Energy Infrastructure ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PIPE\",market:\"US\",,,undefined,":[{"executeDate":"2025-03-24","recordDate":"2025-03-24","paymentDate":"2025-03-28","value":0.09,"currency":"USD"},{"executeDate":"2025-04-21","recordDate":"2025-04-21","paymentDate":"2025-04-25","value":0.09,"currency":"USD"},{"executeDate":"2025-05-19","recordDate":"2025-05-19","paymentDate":"2025-05-23","value":0.09,"currency":"USD"},{"executeDate":"2025-06-23","recordDate":"2025-06-23","paymentDate":"2025-06-27","value":0.09,"currency":"USD"},{"executeDate":"2025-07-21","recordDate":"2025-07-21","paymentDate":"2025-07-25","value":0.09,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PIPE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PIPE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529358353","title":"TruGolf Reports 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529358353","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529358353?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:27","pubTimestamp":1745267220,"startTime":"0","endTime":"0","summary":"Salt Lake City, Utah, April 21, 2025  -- TruGolf Holdings, Inc. , a leading provider of golf simulator software and hardware, announced today an overview of its 2024 results that were filed on Form 10-K on April 15, 2025. The Company reported record sales of $21.9 million, an increase of 6.2% percent as compared to 2023 sales. The gains were driven by continued enthusiastic market adoption of new hardware and software products launched earlier in 2024. Net losses narrowed by 14.5% to  million for 2024, versus a net loss of  million in 2023. Notably, 42% of the net loss for 2024 was due to non-cash expenses. EPS for the full year was , a significant improvement from 2023’s  loss per share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trugolf-reports-2024-financial-results-202700998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRUG","PIPE","BK4085"],"gpt_icon":0},{"id":"2526054472","title":"Stratasys Secures $120 Million Investment from Fortissimo Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2526054472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526054472?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:57","pubTimestamp":1744318635,"startTime":"0","endTime":"0","summary":"Stratasys ( ($SSYS) ) has provided an announcement. On April 8, 2025, Stratasys completed a $120 million private investment in public equity (PIPE)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stratasys-secures-120-million-investment-from-fortissimo-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stratasys-secures-120-million-investment-from-fortissimo-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4170","BK4161","PIPE","BK4546","SSYS"],"gpt_icon":0},{"id":"2524888213","title":"Press Release: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2524888213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524888213?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:05","pubTimestamp":1743710700,"startTime":"0","endTime":"0","summary":"-- Strategic collaboration with LaunXP for the development of vebreltinib in. combination with an EGFR inhibitor  to bring in $10 million. upfront payment and expand dataset to combination therapy. -- New interim data for the vebreltinib development program, including in. non-CNS MET fusion tumors and non-small cell lung cancer  with MET. reductions expected to provide cash runway into the first quarter of 2026. \"In addition, preliminary results we announced in 2024 for various SPARTA cohorts highlight the opportunity for vebreltinib in the treatment of various tumors with c-Met dysregulation. This includes new interim data for the treatment of NSCLC with MET Amplification, new interim data for the treatment of non-CNS solid tumors with MET fusions, and an incremental update for NSCLC with Met Exon 14 skipping,\" continued Dr. Yu.patient with intrahepatic bile duct cancer). Alongside the","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLM","APLMW","PIPE","ORR","LU2065732104.USD","BK4139","PRGS","BK4097"],"gpt_icon":0},{"id":"2524257934","title":"Ernexa Therapeutics Closes New Funding Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2524257934","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524257934?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:55","pubTimestamp":1743684900,"startTime":"0","endTime":"0","summary":"Comes on the heels of company’s rebranding and new strategic direction, advancing its lead program in ovarian cancer. CAMBRIDGE, Mass., April 03, 2025  -- Ernexa Therapeutics , developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock , at a purchase price of $0.1046 per share for an aggregate purchase price of approximately $7,250,000, assuming the Company receives stockholder approval.“These are very exciting times at Ernexa, as we advance therapeutic innovation in cell therapy for the benefit of patients with cancer and autoimmune disease,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “Our approach has been deliberate and strategic, from our investment round at the end of last year to our rebranding last month. With this latest round, we’re doubling d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ernexa-therapeutics-closes-funding-round-125500118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PIPE","LENZ","BK4139","ERNA"],"gpt_icon":0},{"id":"2523917896","title":"ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917896","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917896?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease. PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026. CAMBRIDGE, Massachusetts, March 31, 2025  -- ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease , amyotrophic lateral sclerosis  and multiple system atrophy , today announced financial results for the fiscal year ended December 31, 2024 and provided a corporate update.Based on the encouraging results from the Phase 1a study of PMN310, ProMIS initiated a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/promis-neurosciences-announces-full-2024-110000013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1169590202.USD","LU2211815571.USD","LU0728928796.USD","BK4218","LU0757428866.USD","BK4023","LU1923622291.USD","LU2125909759.SGD","PK","LU1169589451.USD","BK4181","BK4143","BK4178","LU1815336091.USD","PMN","AAN","BK4139","LU2125909916.SGD","LU0053671581.USD","LU1487256676.USD","PIPE","LU1481599808.USD","LU1481600234.SGD","IP","IE00B3T34201.USD","MSA","BK4588","PD","BK4136","LU2463526074.USD"],"gpt_icon":0},{"id":"2521378747","title":"Oncology Institute, Inc. Prepares for PIPE Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521378747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521378747?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:47","pubTimestamp":1742816862,"startTime":"0","endTime":"0","summary":"Oncology Institute, Inc. ( ($TOI) ) has provided an update. The Oncology Institute, Inc. has prepared an investor presentation to discuss a potenti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncology-institute-inc-prepares-for-pipe-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncology-institute-inc-prepares-for-pipe-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PIPE"],"gpt_icon":0},{"id":"2521225015","title":"Ostin Technology Completes PIPE Agreement, Expands Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2521225015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521225015?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:29","pubTimestamp":1742592552,"startTime":"0","endTime":"0","summary":"Ostin Technology Group Co., Ltd. ( ($OST) ) just unveiled an announcement. Ostin Technology Group Co., Ltd. announced that it has completed a secur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ostin-technology-completes-pipe-agreement-expands-share-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ostin-technology-completes-pipe-agreement-expands-share-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PIPE"],"gpt_icon":0},{"id":"2521496186","title":"Press Release: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496186","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496186?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- VCAR33 clinical data update planned for first half of 2025 and trem-cel +. Mylotarg clinical data update planned for second half of 2025. -- Anticipate initiation of the first trem-cel+VCAR33 Treatment System. CAMBRIDGE, Mass., March 20, 2025  -- Vor Bio , a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.\"We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our clinical trials reinforces our confidence in the potential of trem-cel and VCAR33 to transform the treatment landscape,\" said Dr. Robert Ang, Vor Bio's President and Chief Executive Officer. \"With a strengthened financial position from recent investment by new investor Reid Hoffman and existing investor RA Capital Management, we are well-positioned to drive our mission forward and deliver meaningful impact to patients.\".","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PIPE","VOR"],"gpt_icon":0},{"id":"2521965334","title":"Press Release: Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521965334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521965334?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:01","pubTimestamp":1742500860,"startTime":"0","endTime":"0","summary":"Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights. -- Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity  financing --. SOUTH SAN FRANCISCO, Calif., March 20, 2025  -- Senti Biosciences, Inc.  , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of recent pipeline and corporate highlights.Raised gross proceeds of $47.6 million in private investment in public equity  financing: In early December 2024, the Company announced a $37.6 million PIPE financing, followed by an additional $10.0 million later that month as part of the same financing. The financing, which was led by Celadon Partners, with participation from New Enterprise Associates , Leaps by Bayer, Nantahala Ca","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEA","SNTI","BK4539","PIPE"],"gpt_icon":0},{"id":"2519578288","title":"USA Rare Earth and Inflection Point Acquisition Corp. II Announce Closing of Business Combination and Upsized PIPE Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2519578288","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519578288?lang=en_us&edition=fundamental","pubTime":"2025-03-14 01:00","pubTimestamp":1741885200,"startTime":"0","endTime":"0","summary":"USA Rare Earth to Begin Trading on March 14th on the Nasdaq Under New Ticker Symbol “USAR”。On March 14, 2025, USARE’s common stock and public warrants will begin trading on the Nasdaq under the ticker symbol “USAR” and “USARW” respectively.USA Rare Earth is currently building the first phase of its neo magnet facility in Stillwater, Oklahoma which is expected to be operational in early 2026. This first phase is targeting a production capacity of 1,200 metric tons per annum “tpa” and will serve a diverse set of customers and industries. The Company plans to expand capacity to nearly 5,000 tpa in future phases, to beco","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/usa-rare-earth-inflection-point-170000289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPXXU","IPAXU","PIPE","USAR","IPXX","IPXXW"],"gpt_icon":0},{"id":"2517535989","title":"Press Release: Aadi Bioscience Announces Closing of $100 Million PIPE Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517535989","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517535989?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:05","pubTimestamp":1741122300,"startTime":"0","endTime":"0","summary":"MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc.  , an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed,  Invus, Kalehua Capital and other accredited investors, Tae Han,  co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million.Jefferies LLC acted as exclusive placement agent for the private placement.This press release shall not constitute an offer to sell or a solicitation of an offer to buy Aadi's Common Stock, nor shall there be any offer, solicitation, or sale of Aadi's Common Stock in any jurisdiction in which such offer, solicitation or sale would","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AADI","BK4232","BK4139","R","BK4022","PIPE"],"gpt_icon":0},{"id":"2516756415","title":"Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516756415","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516756415?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:19","pubTimestamp":1740867569,"startTime":"0","endTime":"0","summary":"We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Absci Corporation  stands against the other biotech stocks.No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This \"older, richer & sicker\" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you’ll see many more biotech stocks starting to pop to the upside over the coming years.READ NEXT: Why These 15 E-Commerce Stock","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-absci-corporation-absi-skyrocketing-221929466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4121","LU1803068979.SGD","LU2360106780.USD","BK4573","LU0081259029.USD","BK4139","PIPE","BK4529","BK4554","LU1303367103.USD","QID","LU0056508442.USD","LU0823434583.USD","LU1988902786.USD","LU2458330169.SGD","BK4605",".IXIC","LU2054465674.USD","LU1880398554.USD","PSQ","LU0127658192.USD","NVIW.SI","IE00BMPRXN33.USD","USAW.SI","LU1242518857.USD","TQQQ","BK4532","GFS","SQQQ","LU0642271901.SGD","BK4543","NQmain","LU2264538146.SGD","BK4539","LU1064131342.USD","TSYW.SI","USJW.SI","BK4585","LU2458330243.SGD","ABSI","MNQmain","BK4588","LU0979878070.USD","QLD","LU1989764664.SGD","IE0004445239.USD","IE00B5949003.HKD"],"gpt_icon":1},{"id":"2514329905","title":"BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329905","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329905?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:49","pubTimestamp":1740746940,"startTime":"0","endTime":"0","summary":"Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity  financing. Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management. Business combination is expected to be completed in the third quarter of 2025. The combined entity will be named BridgeBio Oncology Therapeutics  and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies. Net proceeds from the transaction are expected to provide BBOT with the capital needed to accelerate the development of three lead programs: BBO-8520, BBO-10203, and BBO-11818. BBO-8520 is a direct inhibitor of KRASG12C in both the \"ON\" and \"OFF\" states and is currently being evaluated in the Phase 1 ONKORAS-101 trial  for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 is an orally bioavailable small molecule","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-bbot-helix-124900685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCO","PIPE","LENZ","BK4139","HLXB"],"gpt_icon":0},{"id":"2514385567","title":"Healthcare Triangle, Inc Announces $15.2 Million PIPE Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385567","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514385567?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:29","pubTimestamp":1740666540,"startTime":"0","endTime":"0","summary":"PLEASANTON, CA - February 27, 2025  - Healthcare Triangle, Inc  , Healthcare Triangle, Inc.  , a leader in digital transformation solutions including managed services, cloud enablement, cybersecurity, and data analytics for the healthcare and life sciences industries, announced today a PIPE offering for gross proceeds of approximately $15.2 million, prior to deducting placement agent fees and other expenses payable by the Company.RBW Capital, LLC  and Spartan Capital Securities, LLC acted as the co-placement agents in connection with the offering.Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/healthcare-triangle-inc-announces-15-142900760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PIPE","HCTI","BK4137","HCSG","BK4167"],"gpt_icon":0},{"id":"2514093462","title":"Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093462","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093462?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025. Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer , resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025. Cash and cash equivalents of $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027. CAMBRIDGE, England & BOSTON, February 25, 2025----Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide  technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicycle-therapeutics-reports-recent-business-120000723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCYC","PIPE","BK4139","ORR","PRGS","BK4097","LENZ","LU2065732104.USD"],"gpt_icon":0},{"id":"2514770399","title":"Invesco Ltd. (IVZ): Among Top Stocks to Buy of Joe DiMenna’s Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2514770399","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514770399?lang=en_us&edition=fundamental","pubTime":"2025-02-25 03:11","pubTimestamp":1740424273,"startTime":"0","endTime":"0","summary":"We recently published a list of Joe DiMenna’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to take a look at where Invesco Ltd.  stands against other top stocks to buy of Joe DiMenna’s portfolio.Zweig-DiMenna Associates Inc.is a U.S.-based hedge fund with a legacy spanning four decades. Established in 1984 by Joseph A. DiMenna and Martin Zweig, the firm specializes in absolute return investing. Its strategies encompass fundamental long/short equities and global macro approaches, positioning it among the longest-running hedge funds in the industry. DiMenna serves as the Managing Director and Chief Investment Officer, overseeing the firm’s partnerships and investment funds.The fund quickly gained prominence for its strong returns. In 1999,BusinessWeekreco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invesco-ltd-ivz-among-top-191113000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EPS","PIPE","BK4585","BK4588","BK4135","IVZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}]}}